National Institute of Infectious Diseases, Tokyo, Japan.
National Institute of Infectious Diseases, Tokyo, Japan.
Vaccine. 2021 Dec 20;39(52):7531-7540. doi: 10.1016/j.vaccine.2021.09.054. Epub 2021 Nov 30.
For elderly people who have low incidence of influenza, calculation of credible vaccine effectiveness (VE) sometimes becomes difficult. Currently, VE for elderly people is insufficient to ascertain the precise efficacy specifically. Cost-effectiveness of influenza vaccination of elderly people is discussed widely in terms of topics and areas. This report describes research results demonstrating influenza vaccination effectiveness among elderly people based on recent findings. Newly available influenza vaccination for elderly people appears to be cost-effective compared with that of trivalent inactiveted influenza vaccine. Overall, for all influenza virus types, it remains unclear whether influenza vaccination shows high VE. A decreasing effect of repeated vaccination was confirmed partially by test negative design and a serological study of cohorts. However, some studies have found no such decreasing effect. Measurement of VE and subsequent analysis of the cost-effectiveness of influenza vaccination for elderly people requires long-term monitoring using serological studies and test negative design.
对于流感发病率较低的老年人,可信疫苗效力(VE)的计算有时会变得困难。目前,针对老年人的 VE 尚不足以确定确切的疗效。老年人接种流感疫苗的成本效益在主题和领域方面都有广泛的讨论。本报告根据最新发现描述了证明老年人接种流感疫苗有效性的研究结果。与三价灭活流感疫苗相比,新的老年人流感疫苗似乎具有成本效益。总体而言,对于所有流感病毒类型,流感疫苗是否具有高 VE 尚不清楚。通过阴性检测设计和队列的血清学研究部分证实了重复接种的效果降低。然而,一些研究并未发现这种效果降低。使用血清学研究和阴性检测设计进行长期监测,以测量 VE 并随后分析老年人接种流感疫苗的成本效益。